What NICE Says About Wegovy and Who Qualifies Under UK Guidance

The clinical evidence NICE examined before recommending Wegovy

NICE's recommendation did not arrive in a vacuum. The committee evaluated the STEP 1 trial, published in the New England Journal of Medicine, which followed adults with obesity or overweight plus a weight-related condition over 68 weeks. Participants taking semaglutide 2.4 mg lost an average of around 15% of body weight compared with just under 3% on placebo. That scale of reduction placed semaglutide well beyond what older treatments could reliably achieve, and it was this data that anchored the committee's positive decision. The trial enrolled people without type 2 diabetes; NICE considered the evidence robust enough to support a recommendation, while acknowledging that real-world adherence and specialist-service delivery would affect outcomes. If you want the full picture of how semaglutide performs against the trial data, our semaglutide and NICE outcomes page goes through the numbers in detail.

Exactly who NICE says Wegovy is for on the NHS

TA875 sets out the qualifying conditions with some precision. Adults need a BMI of at least 35 kg/m², at least one weight-related comorbidity (conditions such as hypertension, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea are the typical examples), and they must be enrolled in a specialist weight management service that provides multidisciplinary support. The two-year time limit is explicit in the guidance: NICE's recommendation is not for indefinite NHS treatment. The committee also built in a clinical-response check — if a patient has not lost at least 5% of their starting weight after six months at the maintenance dose, continuing is reviewed. Ethnic-background adjustments apply throughout: the effective threshold for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds sits at 32.5 kg/m² rather than 35. The full TA875 recommendations chapter sets these out in the committee's own words, and it is worth reading if you are trying to gauge your own position.

The gap between NICE approval and actual NHS access

NICE approval means the NHS in England is legally obliged to fund the treatment, but only for patients who meet the criteria and are referred into a qualifying specialist service. In practice, that last step is the constraint. Specialist weight management services in many areas carry long waiting lists, and not every GP will initiate a referral quickly. The NHS England guidance on weight management injections is honest about the phased and capacity-dependent nature of rollout. For tirzepatide (Mounjaro), NICE issued a separate appraisal in December 2024 with a more complex NHS rollout schedule; you can read how that compares on our NICE semaglutide guidance page. None of this affects private prescribing: a private clinician can prescribe Wegovy to an eligible adult without a specialist-service referral or a two-year cap, provided they are satisfied the medicine is clinically appropriate. Pricing for private treatment varies; our Wegovy cost page covers what to look for and what a legitimate price typically includes.

What happens after NICE approval: practical points for anyone considering Wegovy

Wegovy is a once-weekly subcutaneous injection. The pen sits in the fridge at home between uses, a lot of people keep it in the fridge door, which works fine as long as the temperature stays between 2 and 8°C. Treatment starts at 0.25 mg and is titrated upward by the prescriber over several months; 2.4 mg has been the standard maintenance dose, and the MHRA approved a higher 7.2 mg dose in early 2026 for adults with a BMI of 30 or above. The device itself is straightforward; our Wegovy pen guide explains how it works step by step. Side effects are predominantly gastrointestinal (nausea, loose stools and reduced appetite are the most commonly reported) and tend to be most noticeable in the early weeks of each dose increase, and if you are wondering how everyday foods fit around treatment, our page on Wegovy and ice cream is a useful example of how the reduced-appetite effect plays out in practice. The Wegovy overview page covers both the clinical profile and the questions prescribers hear most often. If you are thinking about whether this is the right path for you, speaking to a prescriber is the clearest next step. Suitability depends on your full medical picture, not the NICE criteria alone.